Two boats imageTwo boats image

When your patients with major depressive disorder are facing an inadequate response to their antidepressant

Consider adding

PrREXULTI®


PrREXULTI® is indicated for use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode.1

REQUEST SAMPLESand/or a REXULTI Rep visit

Click here for additional safety information and for a link to the Product Monograph discussing:

  • Most serious warnings and precautions regarding increased mortality in elderly patients with dementia.
  • Other relevant warnings and precautions regarding body temperature regulation, falls and somnolence, lactose content, postural hypotension, motor and sensory instability, orthostatic hypotension, risk of QT interval prolongation, history of drug abuse, driving and operating machinery, monitoring of blood glucose and body weight, risk factors for weight gain, monitoring of fasting lipid profile, prolactin levels, priapism, complete blood count, leukopenia/neutropenia, venous thromboembolism, serious hypersensitivity reactions, monitoring and laboratory tests, neuroleptic malignant syndrome, tardive dyskinesia, seizures, completed suicide, attempted suicide, suicidal behavior and suicidal ideation, impulse-control disorder, severe cutaneous adverse reactions, dysphagia, pregnancy, breast-feeding, geriatric population.
  • Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available through our medical information department. Call 1-877-341-9245.

CANMAT: Canadian Network for Mood and Anxiety Treatments.

*

See guidelines for complete recommendations.

References: 1. REXULTI Product Monograph. Otsuka Pharmaceutical Co., Ltd. 2. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Can J Psychiatry. 2024;1-47. 3. CANMAT. Data on File. CANMAT Letter to PAAB.